Literature DB >> 4830229

Role of sweat in accumulation of orally administered griseofulvin in skin.

V P Shah, W L Epstein, S Riegelman.   

Abstract

Griseofulvin, an orally effective antimicrobial agent, appears in the stratum corneum within 4-8 h after oral administration. Griseofulvin distribution was found to be highest in the outermost layers of the stratum corneum (level I, 20.8+/-1.5 ng/mg) and lowest inside (level II, 10.0+/-1.5; level III, 7.5+/-2.2 ng/mg). In order to study the precise mechanism of griseofulvin transfer to stratum corneum, the role of sweat in the accumulation of griseofulvin was considered. Heat-induced total body sweating decreased the mean stratum corneum concentration of griseofulvin by 55%, and 200-300 ng of griseofulvin accumulated per ml of sweat. A silicone hydrophobic resin was used to differentiate between "wash-off" and carrier properties of sweat for griseofulvin. Prevention of transepidermal water and sweat loss by (a) topical application of formaldehyde-releasing cream to one palm, (b) occlusion by a 2 x 2-cm patch on one arm, and (c) wearing a rubber glove for 24 h, showed a lower griseofulvin concentration when compared to control areas in the same subjects. The results of the gloved hand experiment show that a complete equilibrium is established at all three levels of stratum corneum, thereby removing the reversed gradient. These results support the hypothesis that a "wick effect" is responsible for the observed reversed drug gradient within the stratum corneum. The results of the experiments suggest that sweat and transepidermal fluid loss play an important role in griseofulvin transfer in stratum corneum.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4830229      PMCID: PMC302663          DOI: 10.1172/JCI107718

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  9 in total

1.  The bioassay of griseofulvin in human stratum corneum.

Authors:  F J ROTH; H BLANK
Journal:  Arch Dermatol       Date:  1960-05

2.  QUANTITATION AND REGIONAL DISTRIBUTION OF SWEAT GLANDS IN MAN.

Authors:  W C Randall
Journal:  J Clin Invest       Date:  1946-09       Impact factor: 14.808

3.  Griseofulvin levels in stratum corneum. Study after oral administration in man.

Authors:  W L Epstein; V P Shah; S Riegelman
Journal:  Arch Dermatol       Date:  1972-09

4.  Determination of griseofulvin in skin, plasma, and sweat.

Authors:  V P Shah; S Riegelman; W L Epstein
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

5.  Excretion of amphetamines in human sweat.

Authors:  T B Vree; A T Muskens; J M van Rossum
Journal:  Arch Int Pharmacodyn Ther       Date:  1972-10

6.  Evaluating sweat gland activity with imprint techniques.

Authors:  D R Harris; B F Polk; I Willis
Journal:  J Invest Dermatol       Date:  1972-02       Impact factor: 8.551

7.  Drug excretion in human eccrine sweat.

Authors:  H L Johnson; H I Maibach
Journal:  J Invest Dermatol       Date:  1971-03       Impact factor: 8.551

8.  The permeability of the sweat gland to nonelectrolytes.

Authors:  S W Brusilow; E H Gordes
Journal:  Am J Dis Child       Date:  1966-10

9.  The permeability of human sweat glands to a series of sulfonamide compounds.

Authors:  J H THAYSEN; I L SCHWARTZ
Journal:  J Exp Med       Date:  1953-09       Impact factor: 14.307

  9 in total
  6 in total

Review 1.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

2.  The effect of an oral therapeutic single-dose of griseofulvin on polymorphonuclear leukocyte migration in a casein gradient.

Authors:  U Bandmann; O Bäck; B Norberg
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

3.  Sweat gland function in dermatophytosis.

Authors:  J Hatzis; A Varelzidis; A Tosca; J Stratigos; J Capetanakis
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

Review 4.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

5.  Orally administered ketoconazole: route of delivery to the human stratum corneum.

Authors:  R Harris; H E Jones; W M Artis
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

6.  In Vitro Skin Delivery of Griseofulvin by Layer-by-Layer Nanocoated Emulsions Stabilized by Whey Protein and Polysaccharides.

Authors:  Daniel P Otto; Anja Otto; Melgardt M de Villiers
Journal:  Pharmaceutics       Date:  2022-03-02       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.